Check Point Software Technologies Ltd vs Quest Diagnostics Inc — how do they compare? Check Point Software Technologies Ltd trades at $129.5 (market cap $13.18B), while Quest Diagnostics Inc trades at $237.51 (market cap $26.21B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Check Point Software Technologies Ltd pays none. Which is the better fit depends on your goals.
| CHKP | DGX | |
|---|---|---|
Market Cap | $13.18B | $26.21B |
Sector | Technology | Health |
52-Week High | $206.91 | $238.50 |
52-Week Low | $112.47 | $173.49 |
Enterprise Value | $12.88B | $31.97B |
Dividend Yield | — | 1.45% |
Signals from Pluang's Aura AI — not financial advice
Check Point Software Technologies (CHKP) trades at $128.21, down 2.23% on the day, reflecting recent bearish pressure. The stock shows strong profitability with a net margin of 37.93% and has beaten earnings estimates for three consecutive quarters. Technical indicators signal a bearish trend, with the price near support at $128. Recent news highlights AI security growth potential and insider selling activity.
The outlook is mixed: valuation appears attractive with a P/E of 13.24, but growth challenges and margin pressures pose risks. Analyst consensus leans neutral with a $146.92 price target, suggesting cautious optimism for recovery driven by AI security demand, though competitive and execution risks remain.
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Trailing returns across standard periods
Latest headlines on both assets
Check Point is a global leader in cybersecurity solutions. It provides comprehensive protection against advanced cyber threats for corporate networks, cloud environments, mobile devices, and critical infrastructure.
Read more on CHKP →Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →